Windgap Medical, Inc. Closes Over $39 Million of Series B-1 Investment, More Than Twenty Percent Over Its Initial GoalZiadWindgap Medical, Inc., a leading specialty pharmaceutical and drug delivery platform company, announced today that it has successfully completed its final close with over $39 million of Series B-1 equity financing, led by Taiwania Capital. This equity round of investment expanded beyond an initial target of approximately $32 million due to strong investor interest. This equity financing is also supported by existing investors, including Shepherd Kaplan Krochuk (SKK) and Molex Ventures (a Koch Industries company), along with new investors including...
VC funding update: Which Boston startups made bank in SeptemberZiadBoston's startups and tech companies were busy in September, pulling in collective billions from VCs and other investors. Here's who raised and what they pulled in: Watertown-based pharmaceutical company Windgap Medical Inc. raised more than $17M in equity. Read more >>
Taiwania Capital Joins Pool of Existing Investors to Fund $17 Million of Series B-1 Investment in Novel Drug Delivery Company, Windgap Medical, Inc.Ziad Windgap Medical, Inc., a leading drug delivery platform company, announced today that it has successfully completed initial closing of over $17 million of Series B-1 equity financing round of investment, led by Taiwania Capital. This equity investment round is also supported by existing investors, including Shepherd Kaplan Krochuk, Molex Ventures (a Koch Industries company), and others. Read more >>
University of Minnesota Twin Cities and Windgap Medical receive $3.2 million NIH grant to develop cyanide antidote autoinjectorZiad The University of Minnesota Twin Cities and Windgap Medical have received a $3.2 million grant from the National Institutes of Health (NIH) to develop a new device to quickly administer a recently developed antidote for cyanide poisoning. Under the grant, researchers from the University’s Center for Drug Design, College of Pharmacy, and Massachusetts-based pharmaceutical company Windgap Medical are collaborating to design an autoinjector. Read more >>
ALK announces new epinephrine auto-injector strategy based on innovative new product for the USAZiad ALK today announced that it has finalised its strategy for entering the US market for epinephrine (adrenaline) auto-injectors (EAIs) and that this will focus on a next-generation EAI in partnership with US-based Windgap Medical. Read more >>
Local company making strides toward longer-lasting EpiPen alternativeZiad It's that time of year again when some parents go on the hunt for an elusive pharmaceutical product. Once again, epinephrine injectable pens — or EpiPens — are in short supply, but a local company is making steady strides toward a possible solution. Read more >>
Windgap Medical Announces Strategic Investment from Molex VenturesZiad Windgap Medical, Inc. announced today that it has finalized a deal to enable a strategic investment from Molex Ventures, LLC, a subsidiary of Koch Industries ("Molex Ventures"). Molex Ventures will be investing into an investment round in Windgap led by the Boston-based firm of Shepherd Kaplan Krochuck, LLC. Read more >>